18 Sep 2020
Tarloxotinib (pan-ErbB tyrosine kinase inhibitor) – Rain Therapeutics
Parameter | Percentage |
Disease control rate | 60% (12/20 evaluable pts) |
Cohort A: | |
Stable disease (SD) | 55% (6/11 pts) |
Progressive disease (PD) | 45% (5/11 pts) |
Cohort B: | |
Tumor reduction by RECIST | 44% (4/9 evaluable pts) |
Partial response (PR) | 22% (2/9 pts) |
Stable disease (SD) | 44% (4/9 pts) |
Progressive disease (PD) | 33% (3/9 pts) |
CI Scientists Remarks:
– Dr. Kowndinya, CI Scientists
info@ciscientists.com
For a subscription, please provide your email id